| Market Capitalization (Millions $) |
103 |
| Shares
Outstanding (Millions) |
11 |
| Employees |
102 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-109 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Adicet Bio Inc is a clinical-stage biotechnology company that is at the forefront of developing cutting-edge therapies for cancer patients. The company was founded in 2015 and is headquartered in Menlo Park, California, with additional locations in Texas and Israel. Adicet Bio is a privately held company and has raised over $253 million in venture capital funding.
Adicet Bio is focused on developing novel immunotherapies that harness the power of the immune system to treat various forms of cancer. The company's platform technology uses ee T cells as a delivery vehicle for chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, enabling the cells to recognize and destroy cancer cells. The company's proprietary technology platform is based on over 20 years of research in the field of ee T cells.
Adicet Bio has a pipeline of several promising therapies in various stages of development, including ADI-001, which is being developed for the treatment of solid tumors. The drug is designed to target the B7-H3 antigen, which is overexpressed on several types of cancer cells, including breast, ovarian, bladder, and lung cancers. The therapy is currently in Phase 1 clinical trials.
Another promising therapy in Adicet Bio's pipeline is ADI-101, which is being developed for the treatment of non-Hodgkin's lymphoma (NHL). The drug incorporates the company's ee T cell platform technology and is designed to target the CD20 antigen, which is present on the surface of B cells. The therapy is currently in preclinical development.
Adicet Bio has a strong team of experienced executives and scientists who are dedicated to advancing innovative cancer therapies. The company is led by CEO Anil Singhal, who has over 20 years of experience in the biotechnology industry. The company's scientific team is led by Dr. Aya Jakobovits, who has a Ph.D. in Immunology from the Weizmann Institute of Science and has over 25 years of experience in the biotechnology industry.
In summary, Adicet Bio Inc is a clinical-stage biotechnology company that uses ee T cells as a delivery vehicle for innovative immunotherapies to treat cancer patients. The company has a strong pipeline of promising therapies in various stages of development and a dedicated team of experienced executives and scientists.
Company Address: 131 Dartmouth Street Boston 2116 MA
Company Phone Number: 503-9095 Stock Exchange / Ticker: NASDAQ ACET
|
